Xenetic Biosciences Inc (XBIO)
Xenetic Biosciences, Inc. is a biotechnology company focused on developing immune-oncology therapies for cancer. Its DNase platform is designed to target neutrophil extracellular traps, or NETs, which are associated with tumor growth, metastasis, and resistance to immunotherapy, chemotherapy, and radiotherapy. The company’s development pipeline includes XBIO-015 for pancreatic carcinoma and other solid tumors, XBIO-020 for solid tumors, and ErepoXen, a PolyXen-based product being developed for anemia in chronic kidney disease patients. Xenetic Biosciences also maintains a sublicensing agreement with Takeda Pharmaceutical Co. Ltd. and additional research, development, licensing, and supply arrangements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. The company is headquartered in Framingham, Massachusetts, and its common stock trades on NASDAQ under the symbol XBIO.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XBIO
|
$3.39
|
32.0% Upside
|
Undervalued
|
Not available
|
Not available
|
Good
|
0.0%
|
November 6, 2026
|
1.0x
|
1.8x
|
6.022 M
|
-449.791 K
|
0.0%
|
80.7%
|
-35.8
|
93.4%
|
